Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Financial Results

Bausch Health Reports 143.6% Surge in Q3 Net Income as Revenues Reach $2,941 Million

Bausch Health delivered a significant increase in profitability during the third quarter of 2026, with net income rising to $436 million. The performance was driven by a 9.7% revenue expansion and improved pricing power in key pharmaceutical segments.

Equipment, medicine, technology, laboratory. Stock photo illustrating Bausch Health Companies' financial results story.
Bausch Health Companies Inc. · Photo: SilvanaGodoy / Pixabay
Results at a glance · $ Million
Metric Q3-26Q3-25
Revenue 2,9412,681
Pretax Income 597.00218.00
Net Income 436.00179.00
Diluted EPS 1.150.48
Net Income YoY
+143.6%

Key highlights

  • Consolidated revenue grew to $2,941 million, up from $2,681 million in the prior-year period
  • Net income surged 143.6% year-over-year to $436 million, or $1.15 per diluted share
  • Pretax income improved to $597 million compared to $218 million in Q3 2025
  • Full-year 2026 consolidated revenue guidance raised to a range of $10,975–$11,175 million
  • Cash and cash equivalents increased to $2.49 billion as of September 30, 2026

How the Period Went

Bausch Health achieved revenue of $2,941 million in the third quarter of 2026, marking a 9.7% increase over the $2,681 million reported in the same period last year. This top-line expansion was accompanied by a significant 143.6% surge in net income, which rose to $436 million from $179 million in Q3-25. Consequently, diluted earnings per share reached $1.15, up from $0.48. These results reflect consistent operational momentum across the company's core segments, particularly within the Salix and Solta Medical units, which benefited from robust demand for gastroenterology and aesthetic treatments respectively.

Margins and Profitability

Pretax income for the quarter reached $597 million, a substantial improvement from the $218 million recorded in the prior-year period. This profitability growth was supported by a 230 basis point expansion in adjusted gross margins to 75%, driven by favorable product mix and improved realized pricing in the Salix segment. While the company saw a decrease in total assets to $25.48 billion—primarily due to the reduction of goodwill and intangible assets—it significantly bolstered its liquidity position. Cash and cash equivalents reached $2.49 billion by the end of September 2026, facilitating a net debt reduction of $521 million during the quarter.

Business Overview

  • Salix Pharmaceuticals: Focused on gastroenterology and hepatology treatments, anchored by the Xifaxan franchise
  • Solta Medical: Global aesthetics segment providing skin-tightening and resurfacing technologies
  • Bausch + Lomb: Controlling interest in the publicly traded eye health leader covering vision care and surgical products
  • International & Diversified: Managing a portfolio of established brands across dermatology, neurology, and dentistry
  • Pipeline Development: Recent initiation of Phase 3 registrational programs for Larsucosterol in alcohol-associated hepatitis

Financial Context

The third quarter performance represents the fourteenth consecutive quarter of year-over-year revenue growth for Bausch Health, excluding its interest in Bausch + Lomb. Following quarterly revenues of $2.52 billion in Q1 and $2.85 billion in Q2, the $2,941 million reported in Q3 led management to raise its full-year 2026 consolidated revenue guidance to a range of $10,975 million to $11,175 million. The company is also actively managing its balance sheet, with a scheduled redemption of approximately $643 million in senior notes due in 2027, highlighting a strategic shift toward deleveraging and financial stabilization.

Industry Landscape

The pharmaceutical industry in 2026 is navigating a landscape of steady demand for specialty medicines and medical devices, balanced against pricing pressures in competitive markets. In the gastroenterology space, Bausch Health’s Xifaxan continues to maintain a leading position, though the sector anticipates headwinds from new Medicare pricing adjustments scheduled for 2027. Peer companies such as Teva and Viatris have similarly prioritized portfolio optimization and debt reduction to address legacy obligations. Meanwhile, the medical aesthetics market remains a high-growth area, with Bausch’s Solta Medical segment benefiting from international distribution expansion despite broader macroeconomic softening in specific regions.

Recent quarters and guidance
DateAnnouncementAmount
28 Oct 2026Q3 2026 consolidated revenues and raised FY 2026 guidanceSource: fool.com$2.94 Billion
29 Jul 2026Q2 2026 consolidated revenues and raised FY 2026 guidanceSource: ir.bauschhealth.com$2.85 Billion
29 Apr 2026Q1 2026 consolidated revenues and reaffirmed FY 2026 guidanceSource: ir.bauschhealth.com$2.52 Billion
18 Feb 2026Q4 2025 consolidated revenues and FY 2026 guidance initiationSource: ir.bauschhealth.com$2.80 Billion
29 Oct 2025Q3 2025 consolidated revenues and raised FY 2025 guidanceSource: ir.bauschhealth.com$2.68 Billion
30 Jul 2025Q2 2025 consolidated revenues and reaffirmed FY 2025 guidanceSource: ir.bauschhealth.com$2.53 Billion
Source verified

SEC filing by Bausch Health Companies Inc. announcing third quarter 2026 financial results.

Read the filing ↗

Track Bausch Health Companies Inc. live

Get the next Bausch Health Companies Inc. SEC filing seconds after it lands.

More in Results & Earnings

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.